Customize your JAMA Network experience by selecting one or more topics from the list below.
Quach HT, Dewan AK, Davis EJ, et al. Association of Anti–Programmed Cell Death 1 Cutaneous Toxic Effects With Outcomes in Patients With Advanced Melanoma. JAMA Oncol. 2019;5(6):906–908. doi:10.1001/jamaoncol.2019.0046
Immune checkpoint inhibitors block key mediators of immune tolerance, producing antitumor responses and autoimmunelike toxic effects.1 Toxic effects indicate immune activation against host tissues, although it remains controversial whether this off-target activity indicates concurrent antitumor immunity.2-4 Herein, we retrospectively studied whether cutaneous toxic effects correlated with outcomes in patients with advanced melanoma treated with immune checkpoint inhibitors.
We reviewed electronic medical records of patients treated with anti–programmed cell death 1 (anti–PD-1) with or without ipilimumab from a single center. We assessed demographics, cutaneous toxic effects, steroid administration, and outcomes by retrospective review. The Vanderbilt University Medical Center institutional review board approved the study, with a waiver of patient consent.
Create a personal account or sign in to: